Proteocyte AI
Better cancer diagnostics
Our novel diagnostic technology, Straticyte™, determines the risk of a head and neck lesion becoming cancerous in the near future. If the risk is high, clinicians can provide early interventions. Clinicians can follow-up effectively with moderate and low risk lesions. Accurate early diagnosis and treatment will drastically improve the clinical outcomes and quality of life for people with head and neck cancer.
06/09/2026
STRATICYTE® is Proteocyte AI’s proteomic test designed to help predict a patient’s 5-year risk of oral squamous cell carcinoma (OSCC) using an existing biopsy specimen—supporting more confident patient care and treatment planning.
By combining AI-driven biomarker analysis with advanced digital pathology, STRATICYTE® goes beyond traditional histology to deliver a personalized 5-year OSCC Risk Score (SRS).
Why clinicians choose STRATICYTE®:
✔ Uses an existing biopsy — no additional surgery required
✔ Supports clinical decision-making with 97% sensitivity & negative predictive value
✔ Helps identify ELEVATED RISK patients who may require escalated management
✔ Supports extended follow-up intervals for LOW-RISK patients
✔ Backed by a growing library of peer-reviewed clinical publications
✔ Broad and expanding insurance coverage across major providers
More insight. More confidence. Better patient management.
Learn more about STRATICYTE®:
👉 https://proteocyte.com/straticyte/
Seattle Jaw Surgery Society of OMS Administrators SPOHNC Mouth Cancer Foundation Osteology Foundation Oral Health Foundation SurgeOn Events
Click here to claim your Sponsored Listing.
Category
Website
Address
Toronto, ON
M5G1L7